Therapeutic Approaches for Alzheimer’s Disease: New Perspectives

Abstract

Alzheimer’s disease (AD) was defined as a neurodegenerative disorder, being more affected in the elderly. It is estimated that every 3.2 seconds a person in the world is affected by the high disease that rate in 2050 to 1 second. Therefore, research has been carried out on new therapeutic approaches, such as Transcranial Photobiomodulation and treatment based on antioxidants, such as Resveratrol. Therefore, the objective is to conduct a literature review on these two approaches and their effects on the treatment of AD. It was carried out according to the PRISMA recommendation and the articles were selected according to the years of publication (between 2015 and 2020) and extracted from the following databases: Science Direct, PubMed PMC, Scopus, PubMed NCBI, SciELO, LILACS, MEDLINE and PEDro. In several studies it has been reported that both therapies provide improvements at the molecular and behavioral level, recovering brain functions, acting in a neuroprotective way, improving quality of life, with few adverse effects and in a less invasive way. Thus, both treatments have numerous benefits that can be useful in the treatment of AD. However, there is a need for further research that includes interventions with greater specificity and control, so that they are defined as ideal doses and treatment protocols.

Effects of α-Humulene and its Nanoparticles in Experimental Model of Alzheimer's Disease: Behavioral Analysis and Anti-Inflammatory Activity

“…Alzheimer's disease (AD) is the most common age-related pathology, affecting approximately 50 million people worldwide [1]. It is defined as a progressive neurodegenerative disorder that causes physical and mental decline gradually, leading the individual to death [2].…”

“…Despite the variety of studies related to AD, the etiology remains poorly understood [3]. However, the pathophysiology of AD can be characterized by some factors, such as the abnormal processing of amyloid precursor protein (APP), causing extracellular deposition of β-amyloid peptide (βA), the loss of cholinergic neurons, and the formation of tau protein neurofibrillary tangles [2].…”

Alzheimer’s Disease: Perspective on Therapeutic Options and Recent Hallmarks in Clinical Research

“…Alzheimer's disease (AD), a kind of dementia that differs from age-associated memory impairment [1]. AD is common in elderly people of the age of 65 and above.…”

“…AD is common in elderly people of the age of 65 and above. It is an irreversible, neurodegenerative, progressive brain disorder [1]. The early symptoms include the difficulty of remembering recent conversations or events, apathy, and depression which may proceed further to impaired communication, disorientation, confusion, poor judgment, behavioural changes, and, ultimately difficulty in speaking, swallowing, and walking too.…”